巨头涉嫌严重造假？最新回应！

Core Viewpoint - The article discusses the controversy surrounding Giant Biological's brand, Kefu Mei, which has been accused of fraud regarding the content of recombinant collagen in its products. The company firmly denies these allegations and asserts compliance with regulatory standards [1][3]. Group 1: Company Response - Giant Biological issued a statement refuting claims of serious fraud and the inability to detect recombinant collagen in its products, emphasizing that all product development and production adhere to relevant regulations [3]. - The company conducted multiple tests on its products, confirming that collagen content exceeds 0.1%, contradicting claims of a mere 0.0177% [3]. - The company has experienced organized smear campaigns since mid-April and plans to pursue legal action against those spreading false information [5]. Group 2: Market Position and Financial Performance - Giant Biological is recognized as a leader in the recombinant collagen market, with its brands including Kefu Mei, Keli Jin, and Xin Gan, offering a range of skincare products [8]. - The company went public on the Hong Kong Stock Exchange in 2022 and has shown consistent revenue growth from 1.19 billion in 2020 to an expected 5.54 billion in 2024, with net profits increasing from 826 million to 2.06 billion in the same period [8].